About Affibody
Affibody is a Healthcare company based in Solna (Sweden) founded in 1998. Affibody has raised $43.28 million across 4 funding rounds from investors including European Investment Bank, Kaupthing and AP3. Affibody has completed 1 acquisition, including Visual Bioinformatics. Its chief executive, as recorded, is David Bejker. Affibody offers products and services including Izokibep. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting. Its legal entity is Affibody Medical AB.
Company details
Developer of antibody mimetic and protein based drug for the treatment of multiple diseases. Its proprietary technology platforms are Affibody molecules is used for developing antibody mimetics monoclonal antibodies and antibody fragments. The leading candidate of the company is for prevention of Alzheimers disease, autoimmune diseases, and psoriasis, along with diagnostic imaging program for metastatic breast cancer.
- Headquarters Solna, Sweden
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website affibody.se
- Social LinkedIn
- Legal Name Affibody Medical Ab
- Annual Revenue$18.09 M (USD)-15as on Dec 31, 2023
- Net Profit-$12.43 M (USD)18as on Dec 31, 2023
- EBITDA-$12.16 M (USD)20as on Dec 31, 2023
- Total Equity Funding$43.28M (USD)
in 4 rounds
- Latest Funding Round$21.24M (USD), Debt – Venture
Dec 2022
- InvestorsEuropean Investment Bank
& 9 more
- Investments & Acquisitions
Products & Services of Affibody
Affibody offers a comprehensive portfolio of products and services, including Izokibep.
Therapeutic for treating specific diseases through biologic mechanisms
Funding Insights of Affibody
Affibody has successfully raised a total of $43.28M across 4 strategic funding rounds. The most recent funding activity was a Debt – Venture round of $21.24 million completed in December 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $43.28M
- Total Rounds 4
- Last Round Debt – Venture — $21.24M
- First Round $28M
(Oct 2001)
- Investors Count 10
All 4 funding rounds of Affibody with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2022 | $21.24M | Debt – Venture | – | – | |
| Mar 2007 | $13.28M | Debt – Conventional | – | – | |
| Mar 2007 | $15.28M | Series D | – | AP3, Stena Sessan | |
| Oct 2001 | $28M | Series C | – | International Biotechnology Trust, Healthcap | – |
10 investors in total: 8 institutional and 2 angel.
Investors in Affibody
Affibody has secured backing from 10 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include European Investment Bank, Kaupthing and AP3.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Finance and advisory services for infrastructure projects are provided. | 1958 | eib.org | Luxembourg, Luxembourg | |
Long-term value is created by Stena Sessan through responsible investments. | stenasessan.se | Stockholm, Sweden | ||
Investment opportunities in biotechnology are facilitated by this trust. | ibtplc.com | London, United Kingdom | ||
| healthcap.eu | ||||
Corporate-backed venture capital firm focused on fintech, energy, and multiple sectors | investorgrowthcapital.com | New York, United States | ||
Venture capital fund focused on early-stage healthcare startups | svhealthinvestors.com | Boston, United States | ||
Operates as a commercial bank providing deposits, loans, and payment services to individual and business customers. | 1982 | kaupthing.com | Reykjavik, Iceland | |
AP3 is tasked with managing Sweden's state pension funds. | ap3.se | Stockholm, Sweden | ||
LJ Lage Jonason | unknown_a3ca3092b31745029 | |||
IK Ingvar Kamprad | unknown_15c140b4907b4924a |
Investor details for Affibody
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Affibody
1 people are tracked at Affibody (1 in leadership).
| Name | Role | Group |
|---|---|---|
David Bejker | CEO & President | Leadership |
Complete people profiles for Affibody
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Affibody
Affibody has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Visual Bioinformatics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Bioinformatics software for genomics data storage and retrieval is developed. | visual-bioinformatics.com | Stockholm, Sweden | 1998 | Jun 2001 | •••• |
Complete acquisition details for Affibody
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Affibody
4 dated milestones of Affibody across 24 years, from founding to its latest funding, stage changes and deals.
- Founded Affibody is founded.
- Acquisition Acquires Visual Bioinformatics.
- Funding First funding round of $28.0M.
- Funding Latest funding round, Debt – Venture, of $21.2M.
Web traffic of Affibody
The website of Affibody (affibody.se) receives about 3K visits a month.
- Monthly visits3K
▼ 22.6% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Affibody
Complete news archive for Affibody
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Affibody
Affibody was founded in 1998 and raised its 1st funding round 3 years after it was founded.
Affibody is headquartered in Solna, Sweden.
David Bejker is the CEO of Affibody, as recorded in our data.
Affibody is a funded company, having raised a total of $43.28M across 4 funding rounds to date. The company's 1st funding round was a Series C of $28M, raised on Oct 2001.
Annual revenue of Affibody is $18.09M as on Dec 31, 2023.
Developer of antibody mimetic and protein based drug for the treatment of multiple diseases. Its proprietary technology platforms are Affibody molecules is used for developing antibody mimetics monoclonal antibodies and antibody fragments. The leading candidate of the company is for prevention of Alzheimers disease, autoimmune diseases, and psoriasis, along with diagnostic imaging program for metastatic breast cancer.
Affibody offers Izokibep.
Affibody has made 1 acquisition, including Visual Bioinformatics.
Affibody has 10 investors. Key investors include European Investment Bank, Kaupthing, AP3, Stena Sessan, and Lage Jonason.
Affibody operates through Affibody Medical Ab.